CAPELLA: Wk 52 Results With Long-Acting SC Lenacapavir in Randomized and Nonrandomized Cohorts of Persons With Multidrug-Resistant HIV

Source: CCO Independent Conference Coverage: Clinical Impact of New HIV Data From Fall 2022 Conferences*
Download Slideset
Washington, DC - October 19-23, 2022; Glasgow, Scotland and virtual - October 23-26, 2022
At Week 52, maintenance therapy with SC lenacapavir in combination with an optimized background regimen was associated with virologic suppression in 78% of heavily treatment–experienced persons with multidrug-resistant HIV infection.
Format: Microsoft PowerPoint (.ppt)
File Size: 250 KB
Released: November 3, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings